Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

1.

Chemical synthesis, docking studies and biological effects of a pan peroxisome proliferator-activated receptor agonist and cyclooxygenase inhibitor.

Santin JR, Uchôa FD, Lima Mdo C, Rabello MM, Machado ID, Hernandes MZ, Amato AA, Milton FA, Webb P, Neves Fde A, Galdino SL, Pitta IR, Farsky SH.

Eur J Pharm Sci. 2013 Mar 12;48(4-5):689-97. doi: 10.1016/j.ejps.2012.12.029. Epub 2013 Jan 7.

PMID:
23305993
2.

Role of an indole-thiazolidine molecule PPAR pan-agonist and COX inhibitor on inflammation and microcirculatory damage in acute gastric lesions.

Santin JR, Daufenback Machado I, Rodrigues SF, Teixeira S, Muscará MN, Lins Galdino S, da Rocha Pitta I, Farsky SH.

PLoS One. 2013 Oct 4;8(10):e76894. doi: 10.1371/journal.pone.0076894. eCollection 2013.

3.

Rosiglitazone induces interleukin-1 receptor antagonist in interleukin-1beta-stimulated rat synovial fibroblasts via a peroxisome proliferator-activated receptor beta/delta-dependent mechanism.

Moulin D, Bianchi A, Boyault S, Sebillaud S, Koufany M, Francois M, Netter P, Jouzeau JY, Terlain B.

Arthritis Rheum. 2005 Mar;52(3):759-69.

4.
5.

Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-gamma, reduces acute inflammation.

Cuzzocrea S, Pisano B, Dugo L, Ianaro A, Maffia P, Patel NS, Di Paola R, Ialenti A, Genovese T, Chatterjee PK, Di Rosa M, Caputi AP, Thiemermann C.

Eur J Pharmacol. 2004 Jan 1;483(1):79-93.

PMID:
14709329
6.

New indole-thiazolidine attenuates atherosclerosis in LDLr(-/-) mice.

César FA, Rudnicki M, de Las Heras B, Boscá L, Lima MC, Pitta IR, Abdalla DS.

Vascul Pharmacol. 2015 Aug;71:174-80. doi: 10.1016/j.vph.2015.03.009. Epub 2015 Apr 11.

PMID:
25869519
7.

Improved nonclinical pharmacokinetics and biodistribution of a new PPAR pan-agonist and COX inhibitor in nanocapsule formulation.

Garcia GM, Oliveira LT, Pitta Ida R, de Lima Mdo C, Vilela JM, Andrade MS, Abdalla DS, Mosqueira VC.

J Control Release. 2015 Jul 10;209:207-18. doi: 10.1016/j.jconrel.2015.04.033. Epub 2015 Apr 27.

PMID:
25931305
9.

Activation of peroxisome proliferator-activated receptor beta/delta inhibits lipopolysaccharide-induced cytokine production in adipocytes by lowering nuclear factor-kappaB activity via extracellular signal-related kinase 1/2.

Rodríguez-Calvo R, Serrano L, Coll T, Moullan N, Sánchez RM, Merlos M, Palomer X, Laguna JC, Michalik L, Wahli W, Vázquez-Carrera M.

Diabetes. 2008 Aug;57(8):2149-57. doi: 10.2337/db08-0176. Epub 2008 Apr 28.

10.

Reduction of carrageenan-induced acute pulmonary inflammation in mice by novel thiazolidinedione derivative LPSF/RA-4.

Barbosa KP, Santos LA, Ribeiro EL, Fragoso IT, Rocha SW, Nunes AK, França ME, Silva BS, Silva AK, Donato MA, Gomes FO, Silva TG, Pitta IR, Pitta MR, Lima MC, Uchôa FD, Galdino SL, Peixoto CA.

Eur J Pharmacol. 2013 Oct 15;718(1-3):197-205. doi: 10.1016/j.ejphar.2013.08.033. Epub 2013 Sep 12.

PMID:
24036257
11.

Apoptotic mimicry: phosphatidylserine liposomes reduce inflammation through activation of peroxisome proliferator-activated receptors (PPARs) in vivo.

Ramos GC, Fernandes D, Charão CT, Souza DG, Teixeira MM, Assreuy J.

Br J Pharmacol. 2007 Jul;151(6):844-50. Epub 2007 May 29.

12.
13.

Peroxisome proliferator-activated receptors and the control of inflammation.

Cabrero A, Laguna JC, Vázquez M.

Curr Drug Targets Inflamm Allergy. 2002 Sep;1(3):243-8. Review.

PMID:
14561188
14.

PPAR activators and COX inhibitors selectively block cytokine-induced COX-2 expression and activity in human aortic smooth muscle cells.

Rival Y, Puech L, Taillandier T, Benéteau N, Rouquette A, Lestienne F, Dupont-Passelaigue E, Le Roy I, Patoiseau JF, Junquéro D.

Eur J Pharmacol. 2009 Mar 15;606(1-3):121-9. doi: 10.1016/j.ejphar.2009.01.010. Epub 2009 Jan 21.

PMID:
19374865
15.

In vitro and in vivo anti-inflammatory activities of columbin through the inhibition of cycloxygenase-2 and nitric oxide but not the suppression of NF-κB translocation.

Ibrahim Abdelwahab S, Syaed Koko W, Mohamed Elhassan Taha M, Mohan S, Achoui M, Ameen Abdulla M, Rais Mustafa M, Ahmad S, Ibrahim Noordin M, Lip Yong C, Roslan Sulaiman M, Othman R, Amir Hassan A.

Eur J Pharmacol. 2012 Mar 5;678(1-3):61-70. doi: 10.1016/j.ejphar.2011.12.024. Epub 2011 Dec 27.

PMID:
22227329
16.

Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.

Oliveira AC, Bertollo CM, Rocha LT, Nascimento EB Jr, Costa KA, Coelho MM.

Eur J Pharmacol. 2007 Apr 30;561(1-3):194-201. Epub 2007 Jan 19.

PMID:
17343847
17.
18.

A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.

Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, Bronfman M.

J Cell Physiol. 2008 Nov;217(2):367-76. doi: 10.1002/jcp.21509.

PMID:
18543250
19.

A novel peroxisome proliferator-activated receptor alpha/gamma agonist, BPR1H0101, inhibits topoisomerase II catalytic activity in human cancer cells.

Kao YH, Hsieh HP, Chitlimalla SK, Pan WY, Kuo CC, Tsai YC, Lin WH, Chuang SE, Chang JY.

Anticancer Drugs. 2008 Feb;19(2):151-8. doi: 10.1097/CAD.0b013e3282f28fe.

PMID:
18176111
20.

Preclinical pharmacokinetic and pharmacodynamic evaluation of thiazolidinone PG15: an anti-inflammatory candidate.

Uchôa Fde T, da Silva TG, de Lima Mdo C, Galdino SL, Pitta Ida R, Dalla Costa T.

J Pharm Pharmacol. 2009 Mar;61(3):339-45. doi: 10.1211/jpp/61.03.0008.

PMID:
19222906

Supplemental Content

Support Center